Biogen Inc.

NasdaqGS:BIIB Stock Report

Market Cap: US$22.6b

Biogen Valuation

Is BIIB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

5/6

Valuation Score 5/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of BIIB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: BIIB ($156) is trading below our estimate of fair value ($713.61)

Significantly Below Fair Value: BIIB is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for BIIB?

Key metric: As BIIB is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for BIIB. This is calculated by dividing BIIB's market cap by their current earnings.
What is BIIB's PE Ratio?
PE Ratio14.1x
EarningsUS$1.62b
Market CapUS$22.65b

Price to Earnings Ratio vs Peers

How does BIIB's PE Ratio compare to its peers?

The above table shows the PE ratio for BIIB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average32.4x
HZNP Horizon Therapeutics
60.8x16.4%US$26.6b
UTHR United Therapeutics
14.6x8.1%US$16.1b
BMRN BioMarin Pharmaceutical
37x27.3%US$11.8b
REGN Regeneron Pharmaceuticals
17.2x7.6%US$80.1b
BIIB Biogen
14.1x12.4%US$22.6b

Price-To-Earnings vs Peers: BIIB is good value based on its Price-To-Earnings Ratio (14.1x) compared to the peer average (22.9x).

Price to Earnings Ratio vs Industry

How does BIIB's PE Ratio compare vs other companies in the US Biotechs Industry?

11 CompaniesPrice / EarningsEstimated GrowthMarket Cap
ROIV Roivant Sciences
1.8x-46.3%US$8.23b
AGIO Agios Pharmaceuticals
4.6x-56.7%US$3.10b
INBX Inhibrx Biosciences
0.1xn/aUS$206.86m
CTMX CytomX Therapeutics
4.9x-35.8%US$69.86m
BIIB 14.1xIndustry Avg. 16.8xNo. of Companies11PE020406080100+
11 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: BIIB is good value based on its Price-To-Earnings Ratio (14.1x) compared to the US Biotechs industry average (16.8x).

Price to Earnings Ratio vs Fair Ratio

What is BIIB's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

BIIB PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio14.1x
Fair PE Ratio27.8x

Price-To-Earnings vs Fair Ratio: BIIB is good value based on its Price-To-Earnings Ratio (14.1x) compared to the estimated Fair Price-To-Earnings Ratio (27.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst BIIB forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$156.00
US$251.70
+61.3%
18.8%US$342.00US$180.00n/a29
Nov ’25US$173.79
US$255.70
+47.1%
17.1%US$342.00US$180.00n/a29
Oct ’25US$190.80
US$270.19
+41.6%
13.7%US$342.00US$190.00n/a30
Sep ’25US$204.76
US$271.42
+32.6%
13.0%US$342.00US$190.00n/a30
Aug ’25US$210.70
US$278.42
+32.1%
13.6%US$350.00US$200.00n/a30
Jul ’25US$231.77
US$283.15
+22.2%
14.4%US$350.00US$200.00n/a30
Jun ’25US$224.94
US$284.78
+26.6%
14.2%US$350.00US$200.00n/a29
May ’25US$216.13
US$286.18
+32.4%
13.4%US$350.00US$200.00n/a31
Apr ’25US$214.83
US$300.47
+39.9%
12.7%US$400.00US$230.00n/a30
Mar ’25US$220.95
US$300.47
+36.0%
12.7%US$400.00US$230.00n/a30
Feb ’25US$247.83
US$313.00
+26.3%
11.1%US$406.00US$245.00n/a30
Jan ’25US$258.77
US$312.61
+20.8%
10.2%US$394.00US$239.00n/a31
Dec ’24US$234.64
US$318.34
+35.7%
11.1%US$394.00US$239.00n/a29
Nov ’24US$239.62
US$324.34
+35.4%
9.2%US$400.00US$266.00US$173.7929
Oct ’24US$257.01
US$327.51
+27.4%
10.5%US$436.00US$269.00US$190.8029
Sep ’24US$267.17
US$325.96
+22.0%
10.2%US$436.00US$269.00US$204.7628
Aug ’24US$269.30
US$335.21
+24.5%
9.7%US$436.00US$276.00US$210.7028
Jul ’24US$284.85
US$336.33
+18.1%
8.5%US$398.00US$263.00US$231.7727
Jun ’24US$302.41
US$334.26
+10.5%
8.4%US$398.00US$263.00US$224.9427
May ’24US$311.11
US$329.48
+5.9%
8.8%US$398.00US$263.00US$216.1327
Apr ’24US$278.03
US$322.50
+16.0%
9.7%US$388.00US$249.00US$214.8326
Mar ’24US$272.21
US$322.19
+18.4%
9.6%US$388.00US$249.00US$220.9526
Feb ’24US$291.60
US$323.69
+11.0%
10.1%US$402.00US$249.00US$247.8326
Jan ’24US$276.92
US$320.35
+15.7%
8.9%US$370.00US$247.00US$258.7726
Dec ’23US$301.85
US$319.38
+5.8%
9.3%US$370.00US$247.00US$234.6426
Nov ’23US$280.04
US$304.88
+8.9%
12.0%US$370.00US$218.00US$239.6226

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.

Discover undervalued companies

IQVIA Holdings

US$34.7b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$194.38

7D

-8.1%

1Y

-7.2%

Collegium Pharmaceutical

US$959.4m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$30.00

7D

-0.6%

1Y

15.5%

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$55.10

7D

-7.9%

1Y

6.6%